EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effects of Baroreflex Activation Therapy on Cardiac Function and Morphology

Ann-Kathrin C Schäfer iD, Manuel Wallbach, Charlotte Schroer, Luca-Yves Lehnig, Stephan Lüders, Gerhard Hasenfuß, Rolf Wachter, Michael J Koziolek

ESC Heart Failure · 01.10.2024 · 11 (5) · 3360-3367

DOI: 10.1002/ehf2.14940 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, online erschienen am 05.07.2024. Verfasst von Ann-Kathrin C Schäfer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Rheumatology, University Medical Centre, Göttingen, Germany. Hauptthemen laut MEDLINE: Baroreflex, Stroke Volume, Heart Failure, Hypertension. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Arterial hypertension (aHTN) plays a fundamental role in the pathogenesis and prognosis of heart failure with preserved ejection fraction (HFpEF). The risk of heart failure increases with therapy-resistant arterial hypertension (trHTN), defined as inadequate blood pressure (BP) control ≥140/90 mmHg despite taking ≥3 antihypertensive medications including a diuretic. This study investigates the effects of the BP lowering baroreflex activation therapy (BAT) on cardiac function and morphology in patients with trHTN with and without HFpEF.

Methods

Sixty-four consecutive patients who had been diagnosed with trHTN and received BAT implantation between 2012 and 2016 were prospectively observed. Office BP, electrocardiographic and echocardiographic data were collected before and after BAT implantation.

Results

Mean patients' age was 59.1 years, 46.9% were male, and mean body mass index (BMI) was 33.2 kg/m2. The prevalence of diabetes mellitus was 38.8%, atrial fibrillation was 12.2%, and chronic kidney disease (CKD) stage ≥3 was 40.8%. Twenty-eight patients had trHTN with HFpEF, and 21 patients had trHTN without HFpEF. Patients with HFpEF were significantly older (64.7 vs. 51.6 years, P < 0.0001), had a lower BMI (30.0 vs. 37.2 kg/m2, P < 0.0001), and suffered more often from CKD-stage ≥3 (64 vs. 20%, P = 0.0032). After BAT implantation, mean office BP dropped in patients with and without HFpEF (from 169 ± 5/86 ± 4 to 143 ± 4/77 ± 3 mmHg [P = 0.0019 for systolic BP and 0.0403 for diastolic BP] and from 170 ± 5/95 ± 4 to 149 ± 6/88 ± 5 mmHg [P = 0.0019 for systolic BP and 0.0763 for diastolic BP]), while a significant reduction of the intake of calcium-antagonists, α2-agonists and direct vasodilators, as well as a decrease in average dosage of ACE-inhibitors and α2-agonists could be seen. Within the study population, a decrease in heart rate from 74 ± 2 to 67 ± 2 min−1 (P = 0.0062) and lengthening of QRS-time from 96 ± 3 to 106 ± 4 ms (P = 0.0027) and QTc-duration from 422 ± 5 to 432 ± 5 ms (P = 0.0184) were detectable. The PQ duration was virtually unchanged. In patients without HF, no significant changes of echocardiographic parameters could be seen. In patients with HFpEF, posterior wall diameter decreased significantly from 14.0 ± 0.5 to 12.7 ± 0.3 mm (P = 0.0125), left ventricular mass (LVM) declined from 278.1 ± 15.8 to 243.9 ± 13.4 g (P = 0.0203), and e′ lateral increased from 8.2 ± 0.4 to 9.0 ± 0.4 cm/s (P = 0.0471).

Conclusions

BAT reduced systolic and diastolic BP and was associated with morphological and functional improvement of HFpEF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BaroreflexStroke VolumeHeart FailureHypertensionHumansMaleFemaleMiddle AgedProspective StudiesEchocardiographyElectrocardiographyFollow-Up StudiesVentricular Function, LeftBlood PressureAgedTreatment OutcomeElectric Stimulation Therapy

Stichwörter der Autor:innen

Baroreflex activation therapyEchocardiographyElectrocardiogramHFpEFResistant hypertension

Autor:innen und Institutionen

  • Department of Nephrology and Rheumatology, University Medical Centre, Göttingen, Germany.
  • German Center for Cardiovascular Research (DZHK), Partner Site, Göttingen, Germany.
  • St. Josefs Hospital, Cloppenburg, Germany.
  • Department of Cardiology and Pulmonology, University Medical Centre, Göttingen, Germany.

ORCID-Profile: Ann-Kathrin C Schäfer

Zitieren

APA

Schäfer, A. C., Wallbach, M., Schroer, C., Lehnig, L. Y., Lüders, S., Hasenfuß, G., Wachter, R., & Koziolek, M. J. (2024). Effects of Baroreflex Activation Therapy on Cardiac Function and Morphology. ESC Heart Failure, 11(5), 3360-3367. https://doi.org/10.1002/ehf2.14940

Vancouver

Schäfer AC, Wallbach M, Schroer C, Lehnig LY, Lüders S, Hasenfuß G, et al. Effects of Baroreflex Activation Therapy on Cardiac Function and Morphology. ESC Heart Failure. 2024;11(5):3360-3367. doi:10.1002/ehf2.14940

BibTeX
@article{Schfer2024,
  author = {Schäfer, Ann-Kathrin C and Wallbach, Manuel and Schroer, Charlotte and Lehnig, Luca-Yves and Lüders, Stephan and Hasenfuß, Gerhard and Wachter, Rolf and Koziolek, Michael J},
  title = {Effects of Baroreflex Activation Therapy on Cardiac Function and Morphology},
  journal = {ESC Heart Failure},
  year = {2024},
  volume = {11},
  number = {5},
  pages = {3360--3367},
  doi = {10.1002/ehf2.14940}
}
Kostenlos starten →